Pulsed low-dose rate re-irradiation for recurrent glioma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of pulsed low-dose rate radiotherapy (pLDRT) as a treatment option for patients with recurrent gliomas. The approach aims to minimize the risk of symptomatic radionecrosis while allowing for higher cumulative radiation doses beyond the conventional limit of 100 Gy. By leveraging the cellular hyper-radiosensitivity at low dose rates, the study seeks to determine the safety and efficacy of this innovative re-irradiation technique. Participants will receive pLDRT after having previously undergone radiation therapy at least six months prior.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years;
* Ability to express appropriate informed consent to treatment;
* Diagnosis of cerebral glioma;
* Histological/radiological confirmation of disease recurrence/relapse;
* Previous brain-level radiation therapy completed a minimum of 6 months;
* Performance status: ECOG=0-2.

Exclusion Criteria:

* Refusal to radiation treatment (i.e., absence of informed consent signed);
* Concomitant chemotherapy;
* Leptomeningeal spread of disease and localization in both cerebral hemispheres;
* Current pregnancy.

Where it's running

• IRCCS-Centro di Riferimento Oncologico (CRO) di Aviano
  Aviano, Pordenone, Italy Recruiting

Study contacts

• Principal investigator: Lorenzo Vinante, MD — Centro di Riferimento Oncologico di Aviano (CRO)
• Study coordinator: Lorenzo Vinante, MD
• Email: lorenzo.vinante@cro.it
• Phone: 0434659855

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• YN003 injection in glioma patients

  This phase 1 study tests whether YN003 injected IV is safe and tolerable for adults with recurrent or progressive glioma, and to explore how the drug behaves in the body and any early signs of activity.

  Recruiting at 2 sites Phase 1 Beijing Inno Medicine Co., Ltd. · Los Angeles, California and 4 other locations · NCT07929909

• Brain connectome project in adults with brain glioma undergoing surgery

  This registry collects MRI data and clinical information from adults with glioma to see how brain networks relate to surgery and recovery.

  Recruiting Northwell Health · New York, New York · NCT07927595

• Proton vs. Photon Radiation for Certain Grade 2–3 Gliomas

  This study tests whether proton therapy can better preserve thinking and memory than photon therapy for adults with IDH-mutated grade 2–3 gliomas who need radiation.

  Recruiting at 2 sites University Hospital, Essen · Essen and 1 other locations · NCT07750457

• Connectome-guided network planning for brain tumor surgery in eloquent areas

  This study tests whether using patient-specific brain network maps from diffusion MRI can help surgeons plan and guide brain tumor removal in eloquent areas.

  Recruiting ARNAS Civico Di Cristina Benfratelli Hospital · Palermo, PA · NCT07717827

• AI-powered analysis of brain MRI to help glioma care

  Doctors will use AI to study existing MRI scans and patient data from adults with glioma to see if it can help with non-invasive diagnosis and treatment planning.

  Recruiting Università degli Studi di Trento · Trento · NCT07703761

• Safusidenib in IDH1-mutant glioma after vorasidenib progression

  This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.

  Recruiting at 2 sites Phase 2 Nuvation Bio Inc. · Los Angeles, California and 11 other locations · NCT07703436

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.